ReviewCurrent infectious disease reports2021
Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV.
Review in Current infectious disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Evaluating B/F/TAF at the first HIV-specialist appointment in antiretroviral naive persons living with HIV: the bifast study.BMC infectious diseases · 2026Trial
- Trial
- Trial
- Cost Considerations for Rapid Start Implementation: Analysis from Seven Rapid Start Provider Sites.AIDS and behavior · 2026Article
- Predicting ART initiation through intertemporal preferences: development and validation of a decision-making preferences scale for ART initiation.BMC public health · 2026Article
- A qualitative assessment of readiness to sustain Rapid Start ART in 14 publicly funded HIV clinics in the United States.Implementation science communications · 2026Article
- Pre-implementation findings on the barriers and potential solutions to initiate same-day antiretroviral therapy among people who inject drugs in Malaysia.The International journal on drug policy · 2025Article
- Estimation of Lifetime Costs Among Insured Persons with HIV in the United States.PharmacoEconomics - open · 2025Article
- Entering HIV Medical Care With AIDS in the Era of Immediate Access to Antiretroviral Treatment.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Pre-exposure Prophylaxis (PrEP) For Prevention of Human Immunodeficiency Virus: A Primary Practice Approach.Journal of general internal medicine · 2025Review
- Unlocking the Keys to Swift HIV Treatment: A Qualitative Exploration of Rapid Antiretroviral Therapy Initiation Among People Living with HIV in China.Patient preference and adherence · 2025Article
- The Predictive Value of Lactate Dehydrogenase for Viral Suppression in Newly Diagnosed People Living With HIV on Antiretroviral Therapy: A Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Traditional healers' knowledge and infection control practices related to HIV in Bukavu City, Democratic Republic of the Congo.BMC public health · 2024Article
- Pharmacist-Driven Rapid Initiation of Antiretroviral Therapy Decreases Time to Viral Suppression in People With HIV.Open forum infectious diseases · 2024Article
- Managing Modern Antiretroviral Therapy in the Intensive Care Unit: Overcoming Challenges for Critically Ill People With Human Immunodeficiency Virus.Open forum infectious diseases · 2024Review
- Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.Clinical microbiology reviews · 2024Review
- Rapid antiretroviral therapy and treatment outcomes among people living with HIV: exploring the mediating roles of medication adherence.Frontiers in public health · 2024Article
- Time from treatment initiation to HIV viral suppression in public care facilities in Brazil: A nationwide linked databases cohort.PloS one · 2024Article
- The Rapid interaction: a qualitative study of provider approaches to implementing Rapid ART.Implementation science communications · 2023Article
- Rapid start antiretroviral therapies for improved engagement in HIV care: implementation science evaluation protocol.BMC health services research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRapid initiation of antiretroviral therapy (ART) is increasingly more common among clinics serving people living with human immunodeficiency virus (PLWH). It is recommended by major guidelines and is especially important in achieving the Getting to Zero (GTZ) goals by 2030. Patients should be offered the option to initiate ART as soon as possible, preferably at time of HIV diagnosis, with the goal of reducing transmission, morbidity, and mortality. RECENT
findingsThree published randomized controlled trials, and several other observational, prospective, and retrospective studies, demonstrated superior rates of viral suppression (VS) with initiation of rapid ART compared to standard of care. Improved time to VS and retention in care were also observed. Based on the regimens studied, a tenofovir backbone combined with an integrase strand transfer inhibitor or protease inhibitor is recommended for rapid start initiation. Since ART is started earlier compared with standard of care, there is opportunity to achieve VS at a much faster rate, especially in the setting of starting on the day of diagnosis. What requires further evaluation is whether or not VS is sustained over time with quicker linkage and initiation of HIV care. SUMMARY: Initiating rapid ART in newly diagnosed PLWH provides a promising approach to achieving GTZ. When offered rapid ART, virologic suppression is improved compared to standard of care, which may reduce transmission and, ultimately, new HIV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.